All Stories

Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 million in biobucks up for grabs per target.

Jun 26, 2025 - 12:25
 0
Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target
Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 million in biobucks up for grabs per target.
Read More

Tags:

Previous Article

Brésil : Skala et Lola From Rio fusionnent pour créer un géant des cosmétiques

Next Article

STAT+: Here’s how Insmed grows to be the next $100 billion biotech

Related Posts

Makary talks DOGE cuts, new voucher program and why FDA still ‘on track’ to meet all PDUFA dates

Makary talks DOGE cuts, new voucher program and why FDA...

Jun 18, 2025  0

Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor from partner Roche

Bayer's Vividion secures rights to world's only clinica...

Jun 4, 2025  0

Bayer-owned BlueRock lays off 50 employees, shuts Cambridge research labs

Bayer-owned BlueRock lays off 50 employees, shuts Cambr...

Jun 25, 2025  0